Hahn, S., Pena, L., Day, J. W., Gambello, M., Gibson, J. B., Hillman, R., … Kishnani, P. S. (2016). 52-week efficacy and safety profile of alglucosidase alfa produced at 4000 liter scale in US patients with Pompe disease: ADVANCE, a phase 4 open-label prospective study. In Molecular Genetics and Metabolism (Vol. 117, pp. S54–S54). Elsevier BV. https://doi.org/10.1016/j.ymgme.2015.12.281

Hahn, Sihoun, Loren Pena, John W. Day, Michael Gambello, James B. Gibson, Richard Hillman, David Kronn, et al. “52-week efficacy and safety profile of alglucosidase alfa produced at 4000 liter scale in US patients with Pompe disease: ADVANCE, a phase 4 open-label prospective study.” In Molecular Genetics and Metabolism, 117:S54–S54. Elsevier BV, 2016. https://doi.org/10.1016/j.ymgme.2015.12.281.

Hahn S, Pena L, Day JW, Gambello M, Gibson JB, Hillman R, et al. 52-week efficacy and safety profile of alglucosidase alfa produced at 4000 liter scale in US patients with Pompe disease: ADVANCE, a phase 4 open-label prospective study. In: Molecular Genetics and Metabolism. Elsevier BV; 2016. p. S54–S54.

Hahn, Sihoun, et al. “52-week efficacy and safety profile of alglucosidase alfa produced at 4000 liter scale in US patients with Pompe disease: ADVANCE, a phase 4 open-label prospective study.” Molecular Genetics and Metabolism, vol. 117, no. 2, Elsevier BV, 2016, pp. S54–S54. Crossref, doi:10.1016/j.ymgme.2015.12.281.

Hahn S, Pena L, Day JW, Gambello M, Gibson JB, Hillman R, Kronn D, Stockton D, Leslie N, Tanpaiboon P, Wang R, Haack KA, Sparks S, Zhao Y, Kishnani PS. 52-week efficacy and safety profile of alglucosidase alfa produced at 4000 liter scale in US patients with Pompe disease: ADVANCE, a phase 4 open-label prospective study. Molecular Genetics and Metabolism. Elsevier BV; 2016. p. S54–S54.